Biomarkers of Efficacy and Tolerability of Sacituzumab-Govitecan in the Treatment of Patients With Triple-negative Breast Cancer in the Metastatic Phase: Prospective Multicenter Real-world Study

RecruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

January 17, 2023

Primary Completion Date

January 17, 2025

Study Completion Date

June 17, 2025

Conditions
Breast Cancer
Interventions
OTHER

data collection

Collection of data relating to the effectiveness of sacituzumab govitecan and evaluation in a real-world context and planned research of predictive biomarkers of efficacy/tolerability

Trial Locations (1)

00144

RECRUITING

"Regina Elena National Cancer Institute", Rome

All Listed Sponsors
collaborator

Ospedale Sandro Pertini, Roma

OTHER

collaborator

Catholic University of the Sacred Heart

OTHER

collaborator

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

collaborator

Campus Bio-Medico University

OTHER

collaborator

Azienda Policlinico Umberto I

OTHER

collaborator

San Giovanni Addolorata Hospital

OTHER

collaborator

"Ospedale SS Annunziata, Chieti"

UNKNOWN

collaborator

"Ospedale Gaetano Bernabeo , Ortona"

UNKNOWN

collaborator

Hospital San Pietro Fatebenefratelli

OTHER

collaborator

presidio Ospedaliero santo spirito in Sassia, Roma

UNKNOWN

collaborator

Ospedale di Belcolle - Viterbo

UNKNOWN

lead

Regina Elena Cancer Institute

OTHER